Cost-effectiveness estimates for antenatal HIV testing in the Netherlands

International Journal of STD and AIDS

Volumn 19, Issue 10, 2008, Pages 668-675

  Rozenbaum, M H ^a   Verweel, G ^b   Folkerts, D K F ^c   Dronkers, F ^a   Van Den Hoek, J A R ^c,d   Hartwig, N G ^b   De Groot, R ^f   Postma, M J ^a,b,e  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AIDS; Antenatal HIV screening; Cost effectiveness analyses; Health economics; Mother to child transmission

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DISEASE REGISTRY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; KAPLAN MEIER METHOD; LIFE EXPECTANCY; NETHERLANDS; PREGNANCY; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SCREENING; VIRUS TRANSMISSION;

ADULT; AIDS SERODIAGNOSIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; NETHERLANDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; QUALITY-ADJUSTED LIFE YEARS;

EID: 53549119421     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008077     Document Type: Article

References (55)

1. van Rossum AMC, van Hirasing RA, de Groot R. Epidemiologische kenmerken van gemelde HIV-1-infectie bij kinderen in Nederland, 1998-2000: verticale transmissie door oudei-s uit gebieden met een gegeneraliseerde epidemie. Ned Tijdschr Geneeskd 2002;146:1282-5
2. De Cock KM, Fowler MG, Merrier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000;283:1175-82
3. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from perinatal studies. The Working Group on Mother-To-Child Transmission of HIV. J Acquit Immune Defic Syndr Hum Retrovirol 1995;8:506-10
4. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS 1997;ll(Suppl. B):S79-87
5. Nolan ML, Greenberg AE, Fowler MG. A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies. AIDS 2002;16:1991-9
6. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94
7. Postma MJ, van den Hoek JA, Beck EJ, et al. [Pharmaco-economic evaluation of mandatory HlV-screening in pregnancy; a cost-efficacy analysis in Amsterdam]. Ned Tijdschr Geneeskd 2000;144:749-54
8. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-65
9. Resino S, Resino R, Maria BJ, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006;43:243-52
10. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br Med J 2003;327:1019
11. Casparie AF, van Hout BA, Simoons ML. [Guidelines and costs]. Ned Tijdschr Geneeskd 1998;142:2075-7
12. Health Care Insurance Board. Richtlijnen voor farmaco-economisch onderzoek [Guidelines for Pharmaco-economic Research] (in Dutch). See [http://www.cvz. nl/] (last checked 12 February 2007)
13. Boveé L, van den Hoek JA. Gemeentelijke geneeskundige en gezondheidsdienst Amsterdam, Afdeling infectieziekten (Annual Reports 2004, 2005, 2006). Department of Infectious Disease, Public Health Service of Amsterdam
14. Postma MJ, Beck EJ, Mandalia S, et al. Universal HIV screening of pregnant women in England: cost effectiveness analysis. Br Med J 1999;318:1656-60
15. Kwee A, Elferink-Stinkens PM, Reuwer PJ, Bruinse HW. Trends in obstetric interventions in the Dutch obstetrical care system in the period 1993-2002. Eur J Obstet Gynecol Reprod Biol 2007;132:70-5
16. Nederlandse vereniging van AIDS behandelaren (NVAB), Nederlandse internisten vereniging. Richtlijn Antiretrovirale behandeling [Guidelines Antiretroviral treatment]. Alphen aan de Rijn: Van zuiden communications B.V., 2005
17. Kwon JA, Yoon SY, Lee CK, et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods 2006;133:20-6
18. Immergluck LC, Cull WL, Schwartz A, Elstein AS. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 2000;105:E54
19. Health Care Insurance Board. Kostprijzen & tarieven medische verrichtingen 2003 [Cost price and tariffs medical action] (in Dutch). See [http://www.cvz.nl] (last checked 15 May 2007)
20. Coll O, Fiore S, Floridia M, et al. Pregnancy and HIV infection: a European consensus on management. AIDS 2002;16(Suppl. 2):S1-18
21. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-93
22. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005;19:795-9
23. Health Care Insurance Board. Prescription database (in Dutch). See [http://www.gipdatabank.nl/] (last checked 8 March 2007)
24. Health Care Insurance Board. Farmacotherapeutisch kompas. Utrecht, The Netherlands: Roto Smeets Utrecht, 2003
25. Prismant. Ziekenhuisstatistieken [Hospital Statistics Database] (in Dutch). See [http://www.prismant.nl/informatieproducten/ ziekenhuisstatistieken/] (last accessed 18 January 2007)
26. Anthony S, Amelink-Verburg MP, Jacobusse GW, van der Pal-de Bruin KM. De thuisbevalling in Nederland 1995-2002. Rapportage over de jaren 2001-2002 (PRNTNO-rapport KvLJPB 2005.083). Bilthoven/Leiden, PRN/TNO, 2005
27. Pacheco SE, Mclntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infect Dis 2006;194:1089-97
28. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005;94:1571-7
29. Lanting CI, van Wouwe JO. Petting Melkvoeding van Zuigelingen 2005. Borstvoeding in Nederland en relatie met certificering door stichting Zorg voor Borstvoeding [Breastfeeding in the Netherlands]. Leiden: TNO, 2006
30. van Rossum AM, Kuiper IE, Rodrigues PR, et al. [Reduction of vertical transmission by means of perinatal prophylaxis in the case of children exposed to HIV-1 and born in the Netherlands during the period 1995-1999]. Ned Tijdschr Geneeskd 2002;146:1277-81
31. van Rossum AM, Geelen SP, Hartwig NG, et al. Results of 2 years of treatment with protease inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:1008-16
32. Statistics Netherlands (in Dutch). See [http://statline.cbs.nl/] (last checked 15 March 2007)
33. Sansom SL, Anderson JE, Farnham PG, et al. Updated estimates of healthcare utilization and costs among perinatally HIV-infected children. J Acquir Immune Defic Syndr 2006;41:521-6
34. Mrus JM, Tsevat J. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care. Med Decis Making 2004;24:30-9
35. Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr 2005;38:163-73
36. Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. Health Serv Res 2004;39:949-67
37. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV infected patients. Clin Infect Dis 2006;42:1003-10
38. Corzillius M, Muhlberger N, Sroczynski G, et al. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir Ther 2004;9:27-36
39. Liddicoat RV, Horton NJ, Urban R, et al. Assessing missed opportunities for HIV testing in medical settings. J Gen Intern Med 2004;19:349-56
40. Klein D, Hurley LB, Merrill D, Quesenberry CP Jr. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003;32:143-52
41. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006;20:1447-50
42. Bramley D, Graves N, Walker D. The cost effectiveness of universal antenatal screening for HIV in New Zealand. AIDS 2003;17:741-8
43. Le CJ, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003;17:2053-61
44. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004;18:2009-17
45. Bunders M, Thome C, Newell ML. Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS 2005;19:1071-9
46. Bos JM, Fennema JS, Postma MJ. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS 2001;15:2031-6
47. Coco A. The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med 2005;3:391-9
48. Graves N, Walker DG, McDonald AM, Kaldor JM, Ziegler JB. Would universal antenatal screening for HIV infection be cost-effective in a setting of very low prevalence? Modelling the data for Australia. J Infect Dis 2004;190:166-74
49. Bramley D, Graves N, Walker D. The cost effectiveness of universal antenatal screening for HIV in New Zealand. AIDS 2003;17:741-8
50. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment naïve HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41:1316-23
51. Hubben GA, Bos JM, Glynn DM, et al. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nationwide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007;25:3669-78
52. Welte R, van den DG, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 2004;23:470-9
53. Health Care Insurance Board. Tariefboek medisch specialisten [Tariffs of medical specialists] (in Dutch). See [www.ctg-zaio.nl] (last checked 15 May 2007)
54. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FHH. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. [Guidelines for costing research, methods and standardized prices for economic evaluations in health care]. Health Care Insurance Board: Diemen, The Netherlands, 2004
55. Arbeidsvoorwaarden per 1 maart 2002, versie 0202. Salarisschalen CAO Academische Ziekenhuizen, bijlage A [Salary scales of Academic Hospitals]